Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
SCRI Development Innovations, LLC
With
If the tumor is HER2neu positive, eligible patients will receive trastuzumab and vinflunine intravenously (IV) every 3 weeks. If the tumor is HER2neu negative, eligible patients will receive vinflunine intravenously (IV) every 3 weeks. Patients whose cancer does not grow or decreases in size may continue to receive treatment until cancer progression. Evaluation of cancer will be every 9 weeks.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted